Home

Mesothelioma

Mesothelioma Treatment

Mesothelioma Specialists

Clinical Trials

Managing Your Care

Veterans Resources

MESOTHELIOMA NEWS ARCHIVE - 2005 to 2006

  1. Onconase is currently being evaluated in a confirmatory Phase IIIb clinical trial in mesothelioma treatment
  2. Results demonstrate that XL647 is generally well tolerated and shows evidence of antitumor activity
  3. INNOVIVE Pharmaceuticals Begins Enrollment in Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer
  4. Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma


  5. FDA approves Zolinza (vorinostat) for cutaneous T-cell lymphoma. This drug is being investigated in other indications including myeloma, mesothelioma and a variety of other cancers
  6. Researchers who led the discovery and development of the Alimta (pemetrexed) named as Heroes of Chemistry by the American Chemical Society
  7. Pivotal trial is evaluating the effectiveness of ONCONASE plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone
  8. Cambridge Antibody Technology to take over development of drug that has shown results in clinical trials in patients with mesothelioma, ovarian and pancreatic cancer
  9. New research findings show that the elusive molecular mechanism that asbestos uses to provoke lung cancer may have been identified
  10. PXD101 is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies
  11. Overall median survival time (MST) favored the ONCONASE + doxorubicin treatment group (12 months) over the doxorubicin group
  12. Over 600 UMM patients have been enrolled in the Onconase Unrespectable Malignant Mesothelioma study
  13. Hilary Calvert believes pemetrexed can be improved to provide longer term survival for some patients
  14. Onconase Clinical Trial Enrollment Expected to Be Ahead of Schedule
  15. Thoracic Cancer Advisory Board will support development of novel ribonuclease (RNase) therapies for the treatment of diseases such as mesothelioma and non-small cell lung cancer
  16. Over 300 patients are now enrolled in the international, confirmatory Phase IIIb trial evaluating ONCONASE® (ranpirnase) as a treatment for unresectable malignant mesothelioma
  17. A significantly higher concentration of osteopontin was detected in patients with diagnosed cases of mesothelioma compared to subjects with asbestos exposure
  18. Company will investigate MORAb-009, a monoclonal antibody targeting mesothelin
  19. First patient in clinical trial gets a second dose of Biogen Idec's new gene drug
  20. Osteopontin reveals the early stages of pleural mesothelioma
  21. New data may provide important treatment advances in mesothelioma and lung cancer
  22. Washington creek possibly causing mesothelioma
  23. Former Congressman's Widow Urges Asbestos Ban
  24. West Dallas Residents Get Asbestos Screening
  25. Diagnostic Tools For Lung And Mesothelioma Cancers To Be Developed

Read excerpts from medical publications

 


    Read excerpts from medical publications

Contact Us













**For a FREE information packet including treatments, clinical trials, and specialists, please complete the form above or call a Mesothelioma Web coordinator at 1-877-367-6376.

News

Resources

If you would like to receive a FREE information packet or have questions about mesothelioma, call us at:

Toll-Free 1-877-367-6376